Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Biotechnology

Healthcare
$9.24 -3.20%

-$0.39 today

Market cap
$326.66M
Beta
0.89
P/E (TTM)
-7.5
EPS (TTM)
-$1.57
52W Low $3.69High $16.33

Volume 0.20M

Average 0.26M

Returns on capital

Contineum Therapeutics, Inc. Class A Common Stock management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-23.0%

avg -37.3%

ROIC

-25.3%

avg -30.4%

ROA

-21.7%

avg -22.6%

Analysis

ROA is currently the strongest return metric at -21.7% versus its period average of -22.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Carmine N. Stengone

President, Chief Executive Officer & DirectorUSD 1.12M5017.22K0.05%

Timothy R. Watkins

Chief Medical Officer & Head of DevelopmentUSD 778.77K52——

Peter T. Slover

Chief Financial OfficerUSD 737.64K51192.00K0.51%

John Healy

General Counsel & Corporate SecretaryUSD 612.78K54——

Daniel S. Lorrain

Chief Science OfficerUSD 565.02K5733.26K0.09%

Steve E. Kunszabo

Senior Director of Investor Relations & Corporate Communications————

Julie S. Iwashita

Senior Vice President of Clinical Operations————

Kristina Haeckl Rac

Senior Vice President of Regulatory Affairs————

Austin Chen

Senior Vice President & Head of Research————

Morgan Paulsen

Senior Manager of Accounting————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 8, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

30

$1.84M

Net Transaction Value

−$1.84M

Net selling

Most Active

Lorrain Daniel S.

18 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 8, 26

Stengone Carmine N.

Direct

Sell$41.1K
Aug 3, 26

Stengone Carmine N.

Direct

Sell$40K
Jul 9, 26

Lorrain Daniel S.

Direct

Sell$400
Jul 8, 26

Stengone Carmine N.

Direct

Sell$40K
Jul 1, 26

Lorrain Daniel S.

Direct

Sell$91.7K
Jul 1, 26

Lorrain Daniel S.

Direct

Sell$40.6K
Jun 30, 26

Lorrain Daniel S.

Direct

Sell$462.3K
Jun 30, 26

Watkins Tim

Direct

Sell$173.6K
Jun 30, 26

Stengone Carmine N.

Direct

Sell$160.1K
Jun 1, 26

Lorrain Daniel S.

Direct

Sell$54.9K

1–10 of 30

Summary

Insiders reported 0 buys worth $0.00 and 30 sells worth $1.84M over the last 12 months. That adds up to net selling of $1.84M. Lorrain Daniel S. was the most active insider with 18 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Contineum Therapeutics, Inc. Class A Common Stock compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CTNM's management, answered from reported figures.

Who manages CTNM?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) lists 10 active executives. The top listed executive is Timothy R. Watkins, Chief Medical Officer & Head of Development.

Are CTNM insiders buying or selling?

Recent insider activity shows net buying of $39.61M.